Continuous Versus Cyclic Use of Oral Contraceptive Pills in Adolescents

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2008 by The Hospital for Sick Children.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
The Physicians' Services Incorporated Foundation
Information provided by:
The Hospital for Sick Children
ClinicalTrials.gov Identifier:
NCT00326404
First received: May 12, 2006
Last updated: July 17, 2008
Last verified: July 2008

May 12, 2006
July 17, 2008
May 2006
May 2008   (final data collection date for primary outcome measure)
The primary objective is to compare the compliance rates of adolescents who take OCPs continuously to those who take OCPs cyclically. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- Our primary objective is to compare the compliance rates of adolescents who take OCPs continuously to those who take OCPs cyclically.
Complete list of historical versions of study NCT00326404 on ClinicalTrials.gov Archive Site
The number of girls who have positive pregnancy test results at 12 months [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- The number of girls who have positive pregnancy test results at 12 months.
Not Provided
Not Provided
 
Continuous Versus Cyclic Use of Oral Contraceptive Pills in Adolescents
Continuous Versus Cyclic Use of an Oral Contraceptive Pills in Adolescents

The primary purpose of this study is to compare the compliance rates of adolescents who take oral contraceptives (OCPs) continuously to those who take OCPs cyclically.

Oral contraceptive pills have traditionally been prescribed in a cyclical manner, where there are 21-24 days of active pills and 4-7 days of placebo pills or a pill-free interval, creating a 28-day cycle. It has now been proven that as long as a woman has both estrogen and progesterone, her uterine lining is protected and is thin. To that effect, a new OCP (Seasonale®, Barr Laboratories, Pomona, NY) has been packaged in the United States that combines 84 days of active pills with 7 days of placebo pills. This allows a withdrawal bleed every 3 months.

Like in adult women, OCPs are the most popular form of birth control and cycle control in adolescents. But, for a variety of reasons, adolescents tend to have poorer compliance when taking OCPs. Adult women tend to be noncompliant about 6% of the time, but, by the end of one year, adolescents have a non-compliance rate of 34-66%.

There have been few studies that even describe improved compliance and decreased ovarian follicular development in women who take OCPs continuously, which could be beneficial in decreasing the rate of adolescent pregnancy. The majority of the studies looking at continuous use of OCPs have been performed in adult women. At present, there has been only one article that has addressed the use of continuous OCPs in adolescents. Sucato and Gold discussed the indications of continuous use of OCPs, how to prescribe them, and what type of progestin to use; but they did not specifically examine compliance or the safety and efficacy of continuous OCPs in adolescents. We plan to evaluate these issues in our study.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Contraception
  • Drug: Desogestrel-Ethinyl Estradiol 21 tablets
    The participants in the continuous study arm will be given 4 packs of Marvelon-21, so that they can take the pills continuously for 84 days followed by no medication for 7 days. During these 7 days, the participant will have a withdrawal bleed. This sequence is repeated by the participant for a total of 12 months. Each patient in the continuous arm will have 4 withdrawal bleeds per year.
    Other Name: Marvelon-21
  • Drug: Desogestrel-Ethinyl Estradiol 28 tablets
    The participants in the cyclical arm of the study will be given 3 packs of Marvelon-28 and asked to take all the pills in the packet, including the placebo pills. During the week of placebo pills, these participants will have a withdrawal bleed. Each patient in the cyclical arm will have 12 withdrawal bleeds per year. The duration of study drug treatment for both arms is 12 months.
    Other Name: Marvelon-28
  • Experimental: 1
    Intervention: Drug: Desogestrel-Ethinyl Estradiol 21 tablets
  • Active Comparator: 2
    Intervention: Drug: Desogestrel-Ethinyl Estradiol 28 tablets
Walpole B, Dettmer E, Morrongiello B, McCrindle B, Hamilton J. Motivational interviewing as an intervention to increase adolescent self-efficacy and promote weight loss: methodology and design. BMC Public Health. 2011 Jun 10;11:459. doi: 10.1186/1471-2458-11-459.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
130
May 2009
May 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female
  • Age 15 to 18
  • Presenting to the Gynecology and Adolescent Medicine Clinic for contraception

Exclusion Criteria:

  • Prior use of the study medication with no improvement in symptoms
  • Any medical condition that indicates continuous OCPs (i.e. acute menorrhagia, dysmenorrhea that did not previously respond to cyclical OCP use)
  • Personal history of or current thromboembolic disorder
  • First-degree relative(s) with thromboembolic disorder
  • Cerebrovascular disease
  • Coronary artery disease
  • Cardiac valvular disease
  • Hypertension (systolic blood pressure > 160 mmHg or diastolic > 100 mmHG)
  • Diabetes with retinopathy/neuromyopathy/nephropathy)
  • Breast cancer
  • Endometrial cancer
  • Undiagnosed abnormal uterine bleeding
  • Cholestatic jaundice of pregnancy
  • Hepatic tumor
  • Known or suspected pregnancy
  • Less than 6 months postpartum if breastfeeding
  • Classic migraine with aura or any other neurological signs
  • Gallbladder disease
  • Taking any medications known to affect the efficacy of OCPs (i.e. phenytoin, phenobarbital, primidone, carbamazepine, griseofulvin, rifampin)
Female
15 Years to 18 Years
No
Contact: Lisa Allen, MD 416-813-6188 lisa.allen@sickkids.ca
Canada
 
NCT00326404
1000008437
No
Lisa Allen/Principal Investigator, The Hospital for Sick Children
The Hospital for Sick Children
The Physicians' Services Incorporated Foundation
Principal Investigator: Lisa Allen, MD The Hospital for Sick Children, Toronto Canada
The Hospital for Sick Children
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP